Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722238 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL13931011 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL23658362 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL23658364 | 1.00 | CHRM2 (0.64) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL156133 | 0.93 | CHRM2 (0.56) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL12875999 | 0.93 | CHRM2 (0.56) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL30968007 | 0.90 | CHRM2 (0.57) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2813407 | 0.89 | CHRM2 (0.59) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL25010681 | 0.86 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2123260 | 0.86 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674908-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-03-09 | — | — | US | claimed |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | claimed |
| EP-1718643-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| JP-2006518367-A | — | — | 2006-08-10 | — | — | JP | claimed |
| US-20060173063-A1 | Exo-(t-butyl 2R(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them | PFIZER INC. | 2006-08-03 | — | — | US | claimed |
| EP-1599483-A1 | EXO-(T-BUTYL 2R(+))-2-AMINO-7-AZABICYCLO 2.2.1 HEPTANE- 7-CARBOXYLATE, INTERMEDIATES, AND PROCESS TO PREPARE AND ISOLATE THEM | Pharmacia & Upjohn Company LLC (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| WO-2004074292-A1 | EXO-(T-BUTYL 2R(+))-2-AMINO-7-AZABICYCLO[2.2.1]HEPTANE-7-CARBOXYLATE, INTERMEDIATES, AND PROCESS TO PREPARE AND ISOLATE THEM | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-09-02 | — | — | WO | claimed |
| EP-4161642-B1 | N-PHENYLAMINOCARBONYL PYRIDINO- , PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | PATHIOS THERAPEUTICS LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4200297-B1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6306876-B1 | DRUGS WITH DIASTERIOMERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6194438-B1 | ANTITUMOR AGENTS; ANTICANCER AGENTS; FARNESYL-PROTEIN TRANSFERASE INHIBITOR | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| EP-1006113-A1 | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth | Pfizer Products Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0971918-A1 | BICYCLIC AMINE DERIVATIVES | ZENECA LIMITED (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998046600-A1 | BICYCLIC AMINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | CHRM2 289/4885CHRM1 178/4885CHRM3 155/4885 |
| US-20080146807-A1 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR3B | CHRM2 393/4885CHRM1 343/4885CHRM3 139/4885 |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | CHRM2 553/4885CHRM1 520/4885CHRM3 382/4885 |
| US-20060173063-A1 | Exo-(t-butyl 2R(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them | EXOC1, EXOC3, EXOC4 | CHRM2 1632/4885CHRM1 1253/4885CHRM3 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.